Consistent with this, CENP-A and HJURP overexpression, which can be driven by p53 loss, are common among various cancer types and have emerged as therapeutic cancer targets because higher levels are correlated with poor prognosis (Filipescu et al, 2017; Mahlke & Nechemia-Arbely, 2020). This evidence concerns the gene HJURP and cancer.